Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

230
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
230
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

139
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
139
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardizing Prurigo Control Assessment Globally: Linguistic Validation and Cross-cultural Adaptation of Prurigo Control Test in 18 Languages.

Acta dermato-venereologica·2026
Same author

A Real-World Cross-Sectional Study on Suspected Mast Cell Activation Syndrome: Multiple Heterogeneous Symptoms Identified.

Clinical and translational allergy·2026
Same author

Why physicians underuse patient-reported outcomes in atopic dermatitis and chronic urticaria - Insights from the UCARE/ADCARE PROMUSE study.

The World Allergy Organization journal·2026
Same author

Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.

The journal of allergy and clinical immunology. In practice·2026
Same author

Differential susceptibility of hair colour changes after barzolvolimab.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026

Related Experiment Video

Updated: May 24, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

944

Remibrutinib in Chronic Spontaneous Urticaria.

Martin Metz1,2, Ana Giménez-Arnau3, Michihiro Hide4,5

  • 1Urticaria Center of Reference and Excellence, Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin.

The New England Journal of Medicine
|March 5, 2025
PubMed
Summary
This summary is machine-generated.

Remibrutinib significantly reduced itch and hives in chronic spontaneous urticaria patients in phase 3 trials. This oral Bruton's tyrosine kinase inhibitor demonstrated sustained efficacy and a similar safety profile to placebo.

More Related Videos

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

8.0K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

Related Experiment Videos

Last Updated: May 24, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

944
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

8.0K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Chronic spontaneous urticaria (CSU) is characterized by recurring itch, hives, or angioedema lasting over six weeks.
  • Remibrutinib, an oral Bruton's tyrosine kinase inhibitor, previously showed positive results in phase 2b trials for CSU.
  • Further data from phase 3 trials were necessary to confirm remibrutinib's efficacy and safety.

Purpose of the Study:

  • To evaluate the efficacy and safety of remibrutinib in patients with symptomatic chronic spontaneous urticaria.
  • To assess the impact of remibrutinib on urticaria activity scores, including itch and hives.
  • To compare remibrutinib's effectiveness against a placebo in patients who had not responded adequately to antihistamines.

Main Methods:

  • Identical, multicenter, double-blind, randomized, placebo-controlled REMIX-1 and REMIX-2 trials were conducted.
  • Patients received either oral remibrutinib (25 mg twice daily) or a placebo in a 2:1 ratio.
  • The primary endpoint was the change in the 7-day Urticaria Activity Score (UAS7) from baseline to week 12.

Main Results:

  • Remibrutinib demonstrated a statistically significant greater reduction in UAS7 at week 12 compared to placebo in both trials (P<0.001).
  • A higher proportion of patients on remibrutinib achieved a UAS7 of 6 or lower and a UAS7 of 0 at week 12 compared to placebo.
  • Adverse event rates were similar between groups, with petechiae being more frequent in the remibrutinib group (3.8% vs. 0.3%).

Conclusions:

  • Oral remibrutinib significantly improved urticaria symptoms, specifically itch and hives, by week 12.
  • The study confirms remibrutinib's efficacy and acceptable safety profile for treating chronic spontaneous urticaria.
  • These findings support remibrutinib as a potential treatment option for CSU patients refractory to antihistamines.